Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† 🔹️ICI for dMMR/MSI-H 🔹️Watch-and-wait approach 🔹️TNT/neoadj ChT 🔹️RT dose 🔹️Restaging timing 🔹️Local excision annalsofoncology.org/article/S0923-…

AIRO 2025⏳ ⏳ ⏳ lnkd.in/dFZfU52w [email protected] #AIRO2025 #radioterapiaoncologica #curadiprecisione

🚭World No Tobacco Day #AIRO #WNTD2025 #TobaccoExposed #UnmaskTheAppeal

🚨SPRING-01🚨 🔍Locally Advanced Rectal Cancer RCT: 25 Gy x 5 ➡️ CAPOX +- Sintilimab 🔥+ Sintilimab demonstrated: ✅⬆️pCR 59% vs 33% ✅No significant adverse surgical or safety signals Time to explore with organ preserving approaches⁉️ #ASCO25

The field of #HeadNeckCancer just got more interesting! #ASCO2025 #Plenary NIVO-POSTOP study was an important IIS for high risk HNSCC Positive DFS @ 3y But signal is primarily locoregional control! Stark contrast to KN689 Kudos to GORTEC Pierre Blanchard, MD Thoughts??

🚨 #ASCO25 plenary NIVOPOSTOP: 1st DFS win in 20+ yrs for resected high-risk LA-SCCHN ➡️ n=666, NIVO + CRT vs CRT alone 🎉 3-yr DFS: 63.1% vs 52.5% 💥HR 0.76 (p=0.034) ⚠️ mild Gr4 AEs ⬆️ w/ NIVO (13.1% vs 5.6%) ✅ New adjuvant IO standard emerging? #hnscc #Immunotherapy #RadOnc

TiP: TRIPLE-SWITCH -- Ph III RCT for adding Doce to ARPIs in mCSPC and subopt PSA resp UroToday.com #ASCO25 🔷n=830 🔷Subopt PSA resp: PSA ≥0.2 ng/mL after 6-12 mos ADT, ≥4 mos ARPI 🔷1:1 cont ADT + ARPI vs cont ARPI + ADT + Doce 🔷Prim EP: OS 🚨 Important RCT for subopt PSA

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage 🔹 Low-risk: Active surveillance; avoid ADT 🔹 Intermediate-risk: Surgery or RT; ADT case-based 🔹 High-risk: Surgery/RT + long-term ADT #EAUguidelines #ProstateCancer Download Cheat Sheet here: uroweb.org/guidelines/pro…

Lymphopenia and ENI It has been long established that H&N radiation leads to lymphopenia, which can last several months. The adverse prognostic impact of lymphopenia has also been shown. However, specific predictors of lymphopenia are poorly understood. Our experience of

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial - ScienceDirect sciencedirect.com/science/articl…

Dr. Andrew Loblaw David Yang Paul Nguyen Deep Chakrabarti Harshani Green 💙 @harshanigreen.bsky.social Alison Tree 💙 Amar Kishan Himanshu Nagar Constantinos Zamboglou Karen Hoffman, MD, MHSc, MPH x.com/VedangMurthy/s… Bag, always the bag. 😊

Thrilled and Grateful. Our review on metastasis-directed therapy in oligometastatic prostate cancer is now out in Seminars in Radiation Oncology. Thank you so much Vedang Murthy Piet Ost for your guidance and belief! Full text authors.elsevier.com/c/1lFrI3lXQoc1…

⏳ Don't miss out! Submit to our Research Topic on Next-Generation Radiotherapy for Prostate Cancer: Precision, Personalization, and Technological Advances 👉 fro.ntiers.in/70397 Drs. Iorio, Morbelli, Ricardi, Oderda and Dal Pra GiuseppeC. Iorio MD Marco Oderda Silvia Morbelli

What comes after disease progression in advanced prostate cancer? The best treatment plan depends on your cancer's traits, your health, and personal preferences. Dr. Alan Dal Pra (Alan Dal Pra, MD) of Sylvester Comprehensive Cancer Center, explains how your risk group helps guide next steps.

🚨What's in a name? Why differentiation between biochemical recurrence and metastatic #prostatecancer matters 👏 New review led by Anael Rizzo David Geffen School of Medicine at UCLA & Pratik Kanabur UCLA Urology 👉Differentiating BCR & metastatic risk groups is 🔑 to help personalize care for our patients

#PORTOS biomarker guides radiation dose escalation in #ProstateCancer treatment. George Zhao, MD UW School of Medicine and Public Health & Alan Dal Pra, MD Sylvester Comprehensive Cancer Center join Alicia Morgans, MD, MPH Dana-Farber to discuss updates to the PORTOS trial and how it predicts radiation benefit in #PCa. #WatchNow >

Ready to elevate your prostate cancer expertise? 🩺 Join the Turin Oncology Prostate cancer (TOP) Masterclass! 🔥 Learn from world experts on the latest diagnosis, treatment, and research. 👉 Join live surgeries, debates, and networking opportunities. 🔗topmasterclass.it

Protecting immune cells before radiation in #ProstateCancer treatment. Dr. Pat Soon-Shiong ImmunityBio, Inc. and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >

📢🗣️ New trial analysis from #FASTRACKII: in kidney cancer, SABR ⬆️ efficacy and ⬇️ cost than radiofrequency or cryoablation #kcsm #radonc 🔹 QALYs: SABR 4.00 vs RFA/CA 3.07 🔹 Cost: SABR A$31,053 vs RFA A$35,001 vs CA A$36,356 🔹 Net savings ~$4K/patient shorturl.at/b7ZOb

🎯 Interested in the 🔗 between PTV margins and Tx-time for prostate SBRT? Check out our latest article 👇🏻👇🏻👇🏻